Company: MGLD
Filing Date: 2025-01-24
Form Type: 424B5
Source: 0001493152-25-003567
Chunk: 48

Company: Marygold Companies, Inc.
Filing Date: 2025-01-24
Form: 424B5
Chunk 48
---
 written notice to Holder. If Company exercises its
deferral right, the outstanding balance automatically increased by 0.85% for each instance that the deferral right is exercised by Company,
which cannot be exercised more than once every ninety calendar days.

Pursuant to the terms of the Purchase Agreement,
beginning on the date of the issuance and sale of the Note and ending 24 months later, Holder will have the right, but not the obligation,
with Company’s prior written consent, to reinvest up to an additional $10,000,000 in the Company on the same terms and conditions
as the Notes (structured as two tranches of $5,000,000 each).

The Company engaged Maxim Group LLC to serve as
placement agent for the transaction between the Company and Holder in exchange for an aggregate commission equal to 7% of the gross cash
proceeds received from the sale of the Notes.

As of September 30, 2024, the note payable balance outstanding, net of the original issue discount and fees paid,
was $3.7 million, of which $2.8 million is due within 12 months from September 30, 2024 and the remaining balance of $0.9 million is
due prior to September 30, 2026.

| 6 |

Securities We May Offer

We may offer shares of our common stock, shares of preferred stock, warrants to purchase our preferred stock or common stock, or a combination of the foregoing securities, either individually or in units, from time to time under this prospectus, together with any applicable prospectus supplement and related free writing prospectus, at prices and on terms determined by market conditions at the time of an offering. Each time we offer securities under this prospectus, we will provide offerees with a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities being offered.

A prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update, or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.

We may sell the securities to or through underwriters, dealers or agents or directly to purchasers. We, as well as any agents acting on our behalf, reserve the sole right